Bio-Path Holdings Inc
BPTH
BPTH: Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
moreShow BPTH Financials
Recent trades of BPTH by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BPTH's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: P-ethoxy nucleic acids for stat3 inhibition Jun. 22, 2021
-
Patent Title: Combination therapy with liposomal antisense oligonucleotides Feb. 23, 2021
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Jan. 26, 2021
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Jul. 02, 2019
-
Patent Title: P-ethoxy nucleic acids for liposomal formulation Aug. 29, 2017
Federal grants, loans, and purchases
Followers on BPTH's company Twitter account
Number of mentions of BPTH in WallStreetBets Daily Discussion
Recent insights relating to BPTH
Recent picks made for BPTH stock on CNBC
ETFs with the largest estimated holdings in BPTH
Flights by private jets registered to BPTH